CP-28,888-27 and placebo nasal sprays were compared in 62 normal volunteers challenged with rhinovirus type 13 or 21 in two randomized, double-blind studies. Half of the subjects received CP-28,888-27 and half received nasal placebo administered at 24, 20, and 16 h before challenge and 4 and 8 h after challenge. In each study, the number of subjects shedding virus in nasal washes, the number developing fourfold or greater serum antibody responses, and the number developing afebrile or febrile upper respiratory tract illness were not significantly different comparing subjects given CP-28,888-27 and those given placebo. Interferon was detected in nasal washes from 5 of 15 volunteers tested in the CP-28,888-27 group compared to 2 of 15 volunteers from the placebo group.
The use of exogenous interferon or interferon inducers to control respiratory viral infections appears attractive because of the diversity of viral families and serotypes that produce common cold syndromes. Some success has already been achieved by this approach. In studies in volunteers, the intranasal application of large quantities of human leukocyte interferon has been shown to reduce the symptoms of rhinovirus, but not those of influenza B illness, and topical application of polyinosinic acid:polycytidylic acid was shown to have some effect in reducing incidence of rhinovirus infections (5, 8) .
Over the past few years a new class of lowmolecular-weight interferon inducers has been developed. The first to be tested was an alkylsubstituted propanediamine referred to as CP-20,961 (1-3, 6, 9, 10, 12) . More recently, a related compound, N,N-dihexadecyl-m-xylylenediamine, purported to be more effective in animals than CP-20,961 and referred to as CP-28,888-27, has been developed (John Niblack, personal communication). We evaluated this drug in experimental rhinovirus infection in volunteers. respiratory tract, and severity of each sign or symptom was recorded on a basis of 1+ to 4+ (e.g., nasal obstruction, cough, etc.). When total symptom scores were analyzed, prechallenge scores on days 0 and -1 were subtracted from the postchallenge scores for each symptom to eliminate minor "background" complaints. In addition, physicians made overall evaluations for presence of illness and site of involvement (e.g., rhinitis, pharyngitis, systemic illness, tracheobronchitis) (1) .
MATERIALS AND METHODS
Virus isolation. A 0.2-ml amount of the nasal washing obtained each day was inoculated onto W1-38 cell cultures, as previously described (1) . The identity of the first isolate from each volunteer was confirmed by neutralization tests, using specific hyperimmune guinea pig serum.
Antibody determination. Neutralizing antibody was measured in sera, using WI-38 cell cultures and 10 TCID50 of homotypic rhinovirus (1).
Interferon assay. Nasal secretions were collected each morning by instilling 10 each symptom and the average duration of each symptom revealed no differences between placebo and CP-28,888-27 groups for either study. DISCUSSION In the present studies, CP-28,888-27, a lowmolecular-weight interferon inducer, was shown to exert no significant effects on virus shedding, illness responses, and serum antibody responses in experimental rhinovirus infection in volunteers. The result is strengthened by the fact that studies performed in two different sites using different virus inocula gave similar results. Rhinovirus type 13 is known to be sensitive to interferon (4) , and the same inoculum had been used in studies with CP-20,961 which demonstrated an effect on severity of illness (1) .
The result occurred despite the fact that a related compound, CP-20,961, had stimulated interferon in nasal washes and exerted prophylactic effects in volunteers against rhinovirus challenges in several different studies (1-3, 9, 10, 12) . In addition, CP-28,888-27 appeared to be a more potent interferon inducer than CP-20,961 in experiments using comparable methods in animal systems. When given in equivalent dosage of 25 mg/kg intraperitoneally in mice, plasma interferon levels were 10-fold higher after CP-28,888-27 administration than after CP-20,961 administration. Not only was interferon stimulation superior with CP-28,888-27 administration than with CP-20,961 administration in mice, but also protection against challenge with vaccinia and encephalomyocarditis viruses was superior with the newer compound. In hamsters, reduction of symptoms due to influenza A virus infection was demonstrated with CP-28,888-27 but not with CP-20,961. Also, interferon stimulation in plasma of rats was demonstrated with CP-28,888-27 but not with CP-20,961. In spite of these in vivo effects, neither CP-20,961 nor CP-28,888-27 stimulates interferon in cell cultures, nor do they confer protection of tissue culture cells against challenge with vesicular stomatitis virus. However, both compounds enhance the protective activity of polyinosinic acid:polycytidylic acid in such cultures, and they are equally potent in this regard.
In our study, neither a clinical effect nor an effect on virus shedding was observed. Interesting, in view of the animal data, were the low titers of nasal wash interferon detected, all specimens containing between 5 and 10 IU. In two prior studies with CP-20,961, a total of 19 of 25 subjects infected with a respiratory virus developed interferon in nasal washes, and titers ranged as high as 2,560 IU with a mean of 1,287 (1, 2). It seems likely that the failure to observe a clinical effect may be related to the failure of CP-28,888-27 to induce large quantities of interferon. Since the stock of CP-28,888-27 used for the present studies had also been used in the animal systems described above, it seems unlikely that the lot of drug used was faulty.
Rather, it appears that in humans, CP-28,888-27 is a less potent interferon inducer than CP-20,961, at least when administered intranasally.
These studies emphasize the significance of species variation in response to interferon inducers. It is apparent that such compounds must be tested in humans to determine potential usefulness. The concept of use of interferon or interferon inducers to control or alleviate viral upper respiratory illness remains valid.
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